165 related articles for article (PubMed ID: 1348409)
1. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.
Tian F; Appert HE; Myles J; Howard JM
Ann Surg; 1992 Apr; 215(4):350-5. PubMed ID: 1348409
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of CA 19-9 serum course in pancreatic cancer.
Safi F; Schlosser W; Falkenreck S; Beger HG
Hepatogastroenterology; 1998; 45(19):253-9. PubMed ID: 9496523
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas.
Glenn J; Steinberg WM; Kurtzman SH; Steinberg SM; Sindelar WF
J Clin Oncol; 1988 Mar; 6(3):462-8. PubMed ID: 3162513
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms.
Safi F; Schlosser W; Kolb G; Beger HG
J Gastrointest Surg; 1997; 1(2):106-12. PubMed ID: 9834336
[TBL] [Abstract][Full Text] [Related]
5. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
6. CA 19-9 serum course and prognosis of pancreatic cancer.
Safi F; Schlosser W; Falkenreck S; Beger HG
Int J Pancreatol; 1996 Dec; 20(3):155-61. PubMed ID: 9013275
[TBL] [Abstract][Full Text] [Related]
7. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer.
Beretta E; Malesci A; Zerbi A; Mariani A; Carlucci M; Bonato C; Ferrari AM; Di Carlo V
Cancer; 1987 Nov; 60(10):2428-31. PubMed ID: 3478117
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Arigami T; Mori S; Ueno S; Shinchi H; Takao S; Natsugoe S
Pancreatology; 2016; 16(6):1051-1056. PubMed ID: 27693096
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of tumour markers CA 19-9 and CA-50 in sera from patients with pancreatic duct carcinoma.
Von Rosen A; Linder S; Harmenberg U; Wiechel KL
Surg Oncol; 1992 Apr; 1(2):109-13. PubMed ID: 1341241
[TBL] [Abstract][Full Text] [Related]
10. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
11. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma.
Rudnicki J; Agrawal AK; Grzebieniak Z; Zukrowski P; Zyśko D; Jelen M; Kielan W; Sebastian M; Słonina J; Marek G; Duda-Barcik Ł
Folia Histochem Cytobiol; 2010 Jan; 48(2):249-61. PubMed ID: 20675282
[TBL] [Abstract][Full Text] [Related]
13. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy.
Katz A; Hanlon A; Lanciano R; Hoffman J; Coia L
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):393-6. PubMed ID: 9607356
[TBL] [Abstract][Full Text] [Related]
15. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
16. Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy.
Liu P; Zhu Y; Liu L
Oncotarget; 2015 Apr; 6(11):9592-9. PubMed ID: 25860937
[TBL] [Abstract][Full Text] [Related]
17. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma.
La Torre M; Nigri G; Cavallini M; Mercantini P; Ziparo V; Ramacciato G
Ann Surg Oncol; 2012 Sep; 19(9):2917-23. PubMed ID: 22488099
[TBL] [Abstract][Full Text] [Related]
18. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.
Montgomery RC; Hoffman JP; Riley LB; Rogatko A; Ridge JA; Eisenberg BL
Ann Surg Oncol; 1997; 4(7):551-6. PubMed ID: 9367020
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
20. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?
Turrini O; Schmidt CM; Moreno J; Parikh P; Matos JM; House MG; Zyromski NJ; Nakeeb A; Pitt HA; Lillemoe KD
J Gastrointest Surg; 2009 Oct; 13(10):1791-7. PubMed ID: 19459018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
